Compare HBB & RLMD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | HBB | RLMD |
|---|---|---|
| Founded | 1904 | 2004 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Home Furnishings | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 418.3M | 461.9M |
| IPO Year | 2017 | 2012 |
| Metric | HBB | RLMD |
|---|---|---|
| Price | $34.48 | $3.36 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $10.75 |
| AVG Volume (30 Days) | 76.7K | ★ 1.2M |
| Earning Date | 11-04-2026 | 11-12-2026 |
| Dividend Yield | ★ 1.44% | N/A |
| EPS Growth | N/A | ★ 45.28 |
| EPS | ★ 2.75 | N/A |
| Revenue | ★ $606,852,000.00 | $13,070.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $12.59 | ★ N/A |
| Revenue Growth | N/A | ★ 154.83 |
| 52 Week Low | $13.75 | $1.80 |
| 52 Week High | $39.99 | $8.00 |
| Indicator | HBB | RLMD |
|---|---|---|
| Relative Strength Index (RSI) | 51.41 | 36.02 |
| Support Level | $18.43 | $3.22 |
| Resistance Level | $39.99 | $4.44 |
| Average True Range (ATR) | 1.89 | 0.19 |
| MACD | -0.45 | 0.00 |
| Stochastic Oscillator | 11.65 | 43.04 |
Hamilton Beach Brands Holding Co, through its subsidiaries, is engaged in consumer, commercial, and specialty small appliances and specialty retail. It designs, markets, and distributes small branded electric household and specialty housewares small appliances, as well as commercial products for restaurants, bars, and hotels. It has two operating segments Home and Commercial Products segment includes consumer product revenue consisting of sales of small electric household and specialty housewares appliances whereas the health segment includes lease revenue associated with leases of connected devices to specialty pharmacy networks and pharmaceutical companies, as well as licensing revenue which grant customers the right to use software for healthcare management.
Relmada Therapeutics Inc is a clinical-stage, publicly traded biotechnology company focused on the development of NDV-01 and sepranolone. NDV-01 is a novel, controlled-release intravesical formulation of gemcitabine and docetaxel. NDV-01 is currently in a Phase 2 clinical trial in Isreal to assess its safety and efficacy in patients with aggressive forms of non-muscle invasive bladder cancer (NMIBC). Sepranolone is a novel neurosteroid epimer of allopregnanolone. sepranolone is being developed for the potential treatment of Prader-Willi Syndrome, Tourette Syndrome, excessive tremor and other diseases related to excessive GABAergic activity.